ResMed Inc.

RMD · NYSE · USD

PoliticiansInstitutionalInsiders

Current holders

Politician	Disclosed
Donald Trump R · EXECUTIVE	net −$262K – $363K 13 disclosures · 7 bought / 6 sold · last Aug 26, 2026
Ro Khanna D · HOUSE · CA	−$203K – $315K −$273K – $429K today 37 filings · last Aug 3, 2026
Alan Armstrong R · SENATE · OK	$1K – $15K $1K – $17K today 1 filing · last Mar 27, 2026
Tommy Tuberville R · SENATE · AL	−$43K – $27K −$45K – $39K today 5 filings · last May 3, 2024
Thomas R. Carper D · HOUSE · DE	−$43K – $27K −$58K – $68K today 5 filings · last Aug 29, 2023
Bradley Scott Schneider D · HOUSE · IL	−$350K – $100K −$934K – $259K today 3 filings · last Feb 5, 2019

Recent transactions

Trades from Oct 10, 2023 – Aug 26, 2026

Politician	Type	Filed after	Amount
Donald Trump R · EXECUTIVE	Sell	43 days Aug 26, 2026 → Oct 8, 2026	≥$15K
Donald Trump R · EXECUTIVE	Sell	76 days Jul 8, 2026 → Sep 22, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Buy	32 days Aug 3, 2026 → Sep 4, 2026	≥$1K
Donald Trump R · EXECUTIVE	Sell	59 days Jun 24, 2026 → Aug 22, 2026	≥$50K
Donald Trump R · EXECUTIVE	Buy	60 days Jun 23, 2026 → Aug 22, 2026	≥$1K
Donald Trump R · EXECUTIVE	Buy	80 days Jun 3, 2026 → Aug 22, 2026	≥$1K
Alan Armstrong R · SENATE · OK	Buy	116 days Mar 27, 2026 → Jul 21, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Sell	6 days Jun 30, 2026 → Jul 6, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Buy	20 days Jun 16, 2026 → Jul 6, 2026	≥$1K
Donald Trump R · EXECUTIVE	Buy	40 days May 22, 2026 → Jul 1, 2026	≥$50K

Congressional trading data provided by QuiverQuant

Institutional

Investors holding

921

13F shares

101.2M

Total invested

$19.7B

Ownership

69.9%

New positions

Closed positions

145

Increased positions

399

Reduced positions

368

Put/Call ratio

2.20

Holder	Reported	Shares	Value	Δ Qtr
BLACKROCK, INC.	8/7/2026	12.3M	$2.4B	+1.85%
VANGUARD CAPITAL MANAGEMENT LLC	8/13/2026	9.5M	$1.8B	+0.08%
VANGUARD PORTFOLIO MANAGEMENT LLC	8/13/2026	7.9M	$1.5B	+0.63%
STATE STREET CORP	9/22/2026	6.7M	$1.3B	+0.57%
GEODE CAPITAL MANAGEMENT, LLC	8/12/2026	4.4M	$845.2M	−0.01%
BANK OF NEW YORK MELLON CORP	8/6/2026	4.2M	$818.0M	−14.78%
FIRST TRUST ADVISORS LP	8/11/2026	2.3M	$444.1M	+48.18%
INVESCO LTD.	8/14/2026	2.1M	$402.1M	+5.47%
MORGAN STANLEY	8/13/2026	1.9M	$375.9M	−28.21%
NORTHERN TRUST CORP	8/13/2026	1.7M	$330.6M	−1.68%
NORDEA INVESTMENT MANAGEMENT AB	8/5/2026	1.4M	$269.6M	+34.32%
DEUTSCHE BANK AG\	8/7/2026	1.3M	$257.7M	−7.07%
UBS GROUP AG	8/13/2026	1.3M	$251.3M	+77.39%
SWEDBANK AB	7/15/2026	1.3M	$248.5M	−5.58%
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P.	8/14/2026	1.2M	$238.2M	—
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	8/14/2026	1.2M	$238.2M	+7.68%
GOLDMAN SACHS GROUP INC	8/14/2026	1.2M	$226.1M	+15.56%
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	8/13/2026	1.1M	$220.2M	+150.91%
DIMENSIONAL FUND ADVISORS LP	8/11/2026	1.1M	$219.0M	+11.89%
LEGAL & GENERAL GROUP PLC	8/14/2026	942.6K	$183.7M	−4.82%
AQR CAPITAL MANAGEMENT LLC	8/14/2026	910.6K	$177.1M	+160.30%
UBS ASSET MANAGEMENT AMERICAS INC	8/13/2026	858.1K	$167.2M	+1.07%
JPMORGAN CHASE & CO	8/12/2026	833.5K	$165.4M	+18.21%
VANGUARD FIDUCIARY TRUST CO	8/13/2026	814.7K	$158.8M	−1.26%
BANK OF AMERICA CORP /DE/	8/14/2026	775.4K	$151.1M	−16.48%

Insider transactions

Insider	Type	Transacted	Price	Date
Farrell Michael J.	M-EXEMPT	5K	$146.34	Oct 7
Farrell Michael J.	M-EXEMPT	5K	$146.34	Oct 7
Farrell Michael J.	S-SALE	5K	$226.33	Oct 7

Analyst consensus

Hold35 analysts

Bearish · 5 · Hold · 16 · Bullish · 14

Earnings history

	EPS	Estimate
Q1 2025	$2.20	$2.04	Beat
Q2 2025	$2.43	$2.32	Beat
Q3 2025	$2.37	$2.38	Miss
Q4 2025	$2.55	$2.46	Beat
Q1 2026	$2.55	$2.51	Beat
Q2 2026	$2.81	$2.74	Beat
Q3 2026	$2.86	$2.80	Beat
Q4 2026	$2.95	$2.89	Beat

Peers

Company overview

IPO dateJun 2, 1995

CEOMichael J. Farrell

Employees11,370

SectorHealthcare

IndustryMedical - Instruments & Supplies

CountryUS

ExchangeNew York Stock Exchange

Websitewww.resmed.com

ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.

Athenic provides research and information tools for educational purposes only and is not a registered investment adviser or broker-dealer. Nothing on this page is investment advice or a recommendation to buy or sell any security. Market data may be delayed. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal.